Trials / Unknown
UnknownNCT00052130
Vaccine Therapy for Patients With Stage III Melanoma
Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy With BCG Plus a Polyvalent Melanoma Vaccine, CancerVax™ Vaccine Versus BCG Plus a Placebo as a Post-Surgical Treatment for Stage III Melanoma
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,118 (planned)
- Sponsor
- CancerVax Corporation · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 3 study in patients with melanoma that has spread to the lymph nodes (stage III), and who have had all of their cancer surgically removed. The purpose of this study is to evaluate the ability of the CancerVax™ vaccine to prevent or slow the recurrence of melanoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CancerVax vaccine (CANVAXIN) |
Timeline
- First posted
- 2003-01-24
- Last updated
- 2005-06-24
Locations
80 sites across 13 countries: United States, Australia, Brazil, Canada, France, Germany, Ireland, Israel, Italy, Netherlands, New Zealand, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT00052130. Inclusion in this directory is not an endorsement.